CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

chlormethine hydrochloride

Last Updated: December 23, 2020
Result type: Reports
Project Number: PC0242-000
Product Line: Reimbursement Review

Generic Name: chlormethine hydrochloride

Brand Name: Ledaga

Manufacturer: Recordati Rare Diseases Canada Inc.

Therapeutic Area: T-cell lymphoma

Indications: For the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.

Manufacturer Requested Reimbursement Criteria1: For the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adult patients.

Submission Type: Initial

Tumour Type: Lymphoma

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule1: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openNovember 23, 2020
Call for patient/clinician input closedJanuary 22, 2021

- Patient input submission received from Lymphoma Canada, Canadian Skin Patient Alliance and Cutaneous Lymphoma Foundation

Submission receivedDecember 21, 2020
Submission acceptedJanuary 12, 2021
Review initiatedJanuary 13, 2021
Draft CADTH review report(s) provided to sponsor for commentApril 16, 2021
Deadline for sponsors commentsApril 27, 2021
CADTH responses on draft review report(s) provided to sponsorMay 31, 2021
Expert committee meeting (initial)June 10, 2021
Draft recommendation issued to sponsorJune 22, 2021
June 24, 2021
Draft recommendation posted for stakeholder feedback-